ArticleAnnals of clinical and translational neurology2018
Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia.
Article in Annals of clinical and translational neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications.Signal transduction and targeted therapy · 2025Review
- A Rare Case of Overlapping Durvalumab-induced Myositis, Takotsubo-like Morphological Changes Caused by Myocarditis, and Myasthenia Gravis.Internal medicine (Tokyo, Japan) · 2024Article
- Update on Neuro-ophthalmic Manifestations of Immune Checkpoint Inhibitors.Current neurology and neuroscience reports · 2024Review
- Peripheral nervous system adverse events associated with immune checkpoint inhibitors.Journal of neurology · 2023Article
- Review
- Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies.Internal medicine (Tokyo, Japan) · 2023Article
- Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.Cancer immunology, immunotherapy : CII · 2022Review
- Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review.Frontiers in oncology · 2022Article
- Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature.Frontiers in pharmacology · 2022Review
- A rare case of nivolumab-related myasthenia gravis and myocarditis in a patient with metastatic gastric cancer.BMC gastroenterology · 2021Article
- Marked Respiratory Failure in an Ambulant Patient with Immune-mediated Necrotizing Myopathy and Anti-Kv1.4 and Anti-titin Antibodies.Internal medicine (Tokyo, Japan) · 2021Article
- Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.Journal of medical case reports · 2021Review
- Immune Checkpoint Inhibitors and Neurotoxicity.Current neuropharmacology · 2021Review
- Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department.Journal of the American College of Emergency Physicians open · 2020Article
- Pembrolizumab-Induced Myasthenic Crisis with HyperCKemia in a Patient with Thymoma.Journal of clinical neurology (Seoul, Korea) · 2020Article
- A case report of nivolumab-induced myasthenia gravis and myositis in a metastatic renal cell carcinoma patient.Urology case reports · 2020Article
- Paraspinal muscle involvement in pembrolizumab-associated myositis.Oxford medical case reports · 2020Article
- The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma.Case reports in immunology · 2020Article
- Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case report.Thoracic cancer · 2019Article
- Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma.Case reports in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors sometimes cause neuromuscular adverse events. Although a few cases of myasthenia gravis with hyperCKemia triggered by immune checkpoint inhibitors have been described, conclusive evidence remains limited. We conducted a systematic review of published cases of myasthenia gravis with hyperCKemia related to immune checkpoint inhibitors. Moreover, we tested anti-striational antibodies in the case of myasthenia gravis with myositis after nivolumab administration. We located 17 published case reports. Anti-striational antibodies were tested in six cases and five cases were positive. Our systematic analyses revealed poor prognosis in myasthenia gravis combined hyperCKemia with immune checkpoint inhibitors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.